

Rebecca J. Brown, M.D., M.H.Sc.

Curriculum Vitae

20 September 2019

Current Position

2015 – Present Lasker Clinical Research Scholar, Tenure track
Acting Chief, Section on Translational Diabetes and Metabolic Syndromes
Diabetes, Endocrinology, and Obesity Branch
NIDDK/NIH
Bethesda, MD 20892

Former Positions

2012 – 2015 Assistant Clinical Investigator
NIDDK/NIH
Bethesda, MD 20892

2008 - 2012 Senior Fellow in Clinical Research
NIDDK/NIH
Bethesda, MD 20892

2005 - 2008 Clinical Fellow in Pediatric Endocrinology
NICHD/NIH
Bethesda, MD 20892

2002 – 2005 Resident in Pediatrics
Rainbow Babies and Children's Hospital
Cleveland, OH 44106

Education

Duke University – Master of Health Science in Clinical Research, 2010
Mayo Medical School – Doctor of Medicine, 2002
Rice University – Bachelor of Arts in Chemistry, magna cum laude, 1997

Licensure and Board Certification

American Board of Pediatrics, Pediatric Endocrinology (ABP ID 66243, valid 11/2009-12/2019)
Maryland Board of Physicians, Medical License (D0063252, valid through September 30, 2020)

Leadership Roles and Activities

Grant reviewer, UO1 intramural/extramural collaborative grants (2019)
Nancy Nossal Award (intramural grant review), Selection Committee Member (2019)
NIH IRB, Member (2019-present)
NIH Clinicopathologic Grand Rounds Selection Committee, Member (2017-present)
NIDDK/NIAMS IRB, Member (2016-present)
NIDDK Staff Clinician Review Committee, Member (2016-present)
Pediatric Endocrine Society Rare Diseases Committee, Member (2015-2019)
Pediatric Endocrine Society Consensus Statement on the Diagnosis and Management of
Lipodystrophy, Chair (2014-2016)
Lipodystrophy Connect, worldwide patient registry for individuals with lipodystrophy, Governing
board member (2013-2016)

Interinstitute Endocrinology Fellowship Program, Faculty (2012-present)
ILSI North America Low-Calorie Sweeteners Project Committee, Scientific Advisor (2010 to 2014)
Clinical Research Informatics System User's Group Committee, Member (2010-2013)
Patient Portal Clinical Documentation Committee, Member (2012-2013)
Camp Possibilities (non-profit camp for children with type 1 diabetes), Assistant Medical Director and member of Board of Directors (2008-present)
Admissions Committee for HHMI-NIH Cloister Scholars Program, Member (2008-2011)
NICHD Pediatric Endocrinology Fellowship Program, Faculty (2008-present)
Pediatric Endocrine Society, Member (2006-present)
Endocrine Society, Member (2006-present)
NICHD Quality Assurance Committee, Member (2006- 2007)
NIH Pediatric Endocrinology Training Program Fellows Representative (2006-2007)

Honors, Awards, and Recognitions

Best teacher award from NIH Adult Endocrinology Fellowship training program (2019)
Selected as one of 6 "Best of 2017" papers in J Clin Endocrinol Metab: Brown RJ, et al. Effects of Metreleptin in Pediatric Patients with Lipodystrophy J Clin Endocrinol Metab. 2017 Jan 23.
Best laboratory award from NIH Adult Endocrinology Fellowship training program (2017)
Nominee for NIH Distinguished Postbac Mentor Award (2017)
Nominee for NIH Distinguished Clinical Teacher Award (2016)
NIDDK Director's Award (Group), "For selfless accommodation of requests to share time and expertise in intramural research, going above and beyond to widely and well convey the NIDDK mission" (2012)
European Society for Pediatric Endocrinology Science School Award (2011)
Scholars Abstract Award, ACRT/SCTS Annual Meeting (2010)
American Diabetes Association Travel Award (2008)
Endocrine Fellows Foundation Preceptorship Award (2007)
Lawson Wilkins Pediatric Endocrine Society Travel Award (2007)
Neonatology Clinical Excellence Award, Rainbow Babies and Children's Hospital (2004)
Excellence in Patient Care Award, Rainbow Babies and Children's Hospital (2003)
Outstanding Teaching Resident Award, Rainbow Babies and Children's Hospital (2003)
Howard Hughes Medical Institute Scholarship (2000-2002)
Howard Hughes Medical Institute Cloister Scholar, NIH, Bethesda, MD (1999-2000)
Phi Beta Kappa Honor Society, Rice University, Houston, TX (1997)
Zevi and Bertha Salsburg Memorial Award in Chemistry, Rice University, Houston, TX (1997)
Sigma Pi Upsilon Chemistry Honor Society, Rice University, Houston, TX (1995)

Bibliography

Peer Reviewed Publications

1. Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, Cheung HC, Bradt P, Foss de Freitas MC, Montenegro RM, Fernandes VO, **Cochran E, Brown RJ**. Comorbidities and Survival in Patients with Lipodystrophy: An International Chart Review Study. *J Clin Endocrinol Metab*. 2019 Jul 17. pii: jc.2018-02730.
2. **Kinzer AB**, Shamburek RD, **Lightbourne M**, Muniyappa R, **Brown RJ**. Advanced Lipoprotein Analysis Shows Atherogenic Lipid Profile in Lipodystrophy Patients That Improves After Metreleptin. *Journal of the Endocrine Society*. Accepted.

3. **Sekizkardes H, Cochran E, Malandrino N, Garg A, Brown RJ.** Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants. *J Clin Endocrinol Metab.* 2019 Aug 1;104(8):3068-3076.
4. **Lee HL, Waldman MA, Auh S, Balow JE, Cochran EK, Gorden P, Brown RJ.** Effects of metreleptin on proteinuria in patients with lipodystrophy. *J Clin Endocrinol Metab.* 2019 Apr 16. pii: jc.2019-00200.
5. Sánchez-Iglesias S, Crocker M, O'Callaghan M, Darling A, García-Cazorla A, Domingo-Jiménez R, Castro A, Fernández-Pombo A, Ruibal A, Aguiar P, Garrido-Pumar M, Rodríguez-Núñez A, Álvarez-Escudero J, **Brown RJ, Araújo-Vilar D.** Celia's encephalopathy and c.974dupG in *BSCL2* gene: a hidden change in a known variant. *Neurogenetics.* 2019 May;20(2):73-82.
6. Oral EA, Gorden P, **Cochran E, Araújo-Vilar D, Savage DB, Long A, Fine G, Salinardi T, Brown RJ.** Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. *Endocrine.* 2019 Feb 25. [Epub ahead of print]
7. **Kushchayeva Y, Soldin SJ, Stolze B, Yu X, Auh S, Lin TC, Skarulis M, Brown RJ.** Comparison of Thyroid Panel by Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry during Transition from Euthyroid to Hyperthyroid State. *Annals Thyroid Res.* 2019; 5(1): 178-184.
8. **Kushchayeva Y, Kushchayev S, Startzell M, Cochran E, Auh S, Dai Y, Lightbourne M, Skarulis M, Brown RJ.** Thyroid abnormalities in patients with extreme insulin resistance syndromes. *J Clin Endocrinol Metab.* 2019 Jan 16. 2019 Jun 1;104(6):2216-2228.
9. **Malandrino N, Reynolds JC, Brychta RJ, Chen KY, Auh S, Gharib AM, Startzell M, Cochran EK, Brown RJ.** Visceral Fat Does Not Contribute to Metabolic Disease in Lipodystrophy. *Obes Sci Pract.* 2019 Jan 24;5(1):75-82.
10. Meral R, Ryan BJ, Malandrino N, Jalal A, Neidert AH, Muniyappa R, Akıncı B, Horowitz JF, **Brown RJ, Oral EA.** "Fat Shadows" From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers. *Diabetes Care.* 2018 Oct;41(10):2255-2258.
11. Klubo-Gwiedzinska J, Lange M, **Cochran E, Semple RK, Gewert C, Brown RJ, Gorden P.** Combined immunosuppressive therapy induces remission in patients with severe type B insulin resistance – a prospective cohort study. *Diabetes Care.* 2018 Nov;41(11):2353-2360.
12. **Brown RJ, Valencia A, Startzell M, Cochran E, Walter PJ, Garraffo HM, Cai H, Gharib AM, Ouwerkerk R, Courville AB, Bernstein S, Brychta RJ, Chen KY, Walter M, Auh S, Gorden P.** Metreleptin improves insulin sensitivity independent of food intake in humans with lipodystrophy. *J Clin Invest.* 2019 May;20(2):73-82.
13. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, Jesus AA, Chapelle DC, Kim H, Dill S, Colbert R, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JG, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, **Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nিকেleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R.** JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. *J Clin Invest.* 2019 May;20(2):73-82.
14. **Brown RJ, Oral EA, Cochran E, Araújo-Vilar D, Savage D, Long A, Fine G, Salinardi T, Gorden P.** Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. *Endocrine.* 2019 May;20(2):73-82.
15. Wu X, Hutson I, Akk AM, Mascharak S, Pham CTN, Hourcade DE, **Brown R, Atkinson JP, Harris CA** 2018 Contribution of Adipose-Derived Factor D/Adipsin to Complement Alternative Pathway Activation: Lessons from Lipodystrophy. *J Immunol* 200:2786-2797
16. Hussain I, Patni N, Ueda M, Sorkina E, Valerio CM, Cochran E, **Brown RJ, Peeden J, Tikhonovich Y, Tiulpakov A, Stender SRS, Klouda E, Tayeh MK, Innis J, Meyer A, Lal P, Godoy-Matos AF, Teles MG, Adams-Huet BA, Rader DJ, Hegele RA, Oral EA, Garg A.** A novel generalized lipodystrophy-associated progeroid syndrome due to recurrent heterozygous LMNA p.T10I mutation. *J Clin Endocrinol Metab.* 2018 Mar 1;103(3):1005-1014.
17. Muniyappa, R., Abel, B.S., Asthana, A., Walter, M.F., **Cochran, E.K., Remaley, A.T., Skarulis, M.C., Gorden, P., and Brown, R.J.** Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy. *J Clin Lipidol.* 2017 11:543-550.

18. Sylvetsky, A.C., Issa, N.T., Chandran, A., **Brown, R.J.**, Alamri, H.J., Aitcheson, G., Walter, M., and Rother, K.I. 2017. Pigment Epithelium-Derived Factor Declines in Response to an Oral Glucose Load and Is Correlated with Vitamin D and BMI but Not Diabetes Status in Children and Young Adults. *Horm Res Paediatr.* 2017;87(5):301-306.
19. Rocha NM, Bulger DA, Frontini A, Titheradge H, Gribsholt SB, Knox R, Page M, Harris J, Payne F, Adams C, Sleigh A, Crawford J, Gjesing AP, Bork-Jensen J, Pedersen O, Barroso I, Hansen T, Cox H, Reilly M, Rossor A, **Brown RJ**, Taylor SI, McHale D, Armstrong M, Oral EA, Saudek V, O'Rahilly SI, Maher ER, Richelsen B, Savage DB, Semple RK. Human biallelic MFN2 mutations induce mitochondrial dysfunction, upper body adipose hyperplasia, and suppression of leptin expression. *Elife.* 2017 Apr 17;6. pii: e23813.
20. **Brown RJ, Meehan CA, Cochran E**, Rother KI, Kleiner DE, Walter M, Gorden P. Effects of Metreleptin in Pediatric Patients with Lipodystrophy *J Clin Endocrinol Metab.* 2017 May 1;102(5):1511-1519.
21. Gupta N, Asi N, Farah W, Almasri J, Moreno Barrionuevo P, Alsawas M, Wang Z, Haymond MW, **Brown RJ**, Murad MH. Clinical features and management of non-HIV related lipodystrophy in children: a systematic review. *J Clin Endocrinol Metab.* 2017 Fe 1;102(2):363-374.
22. **Brown RJ, Joseph J, Cochran E**, Gewert C, Semple R, Gorden P. Type B Insulin Resistance Masquerading as Ovarian Hyperthecosis. *J Clin Endocrinol Metab.* 2017 Jun 1;102(6):1789-1791.
23. **Brown RJ**, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother K, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. *J Clin Endocrinol Metab.* 2016 Dec; 101(12):4500-4511.
24. Sylvetsky AC, **Brown RJ**, Blau JE, Walter M, Rother KI. Hormonal responses to non-nutritive sweeteners in water and diet soda. *Nutrition & Metabolism* 2016; 13:71
25. Robinson C, **Cochran E**, Gorden P, **Brown RJ**. Management of Diabetic Ketoacidosis in Severe Insulin Resistance. *Diabetes Care.* 2016 Aug;39(8):e116-8.
26. **Kassai A**, Muniyappa R, Levenson AE, Walter MF, Abel BS, Ring M, Taylor SI, Biddinger SB, Skarulis MC, Gorden P, **Brown RJ**. Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients with Lipodystrophy. *J Clin Endocrinol Metab.* 2016 Apr;101(4):1790-7.
27. Levenson AE, Haas ME, Miao E, **Brown RJ**, de Ferranti SD, Muniyappa R, Biddinger SB. Effect of Leptin Replacement on PCSK9 in ob/ob and Female Lipodystrophic patients. *Endocrinology.* 2016 Apr;157(4):1421-9.
28. **Meehan CA, Cochran E, Kassai A, Brown RJ**, Gorden P. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. *Expert Rev Clin Pharmacol.* 2016 Jan;9(1):59-68.
29. **Brown RJ**, Chan JL, Jaffe ES, **Cochran E**, DePaoli A, Gautier JF, Vigouroux C, Gorden P. Lymphoma in acquired generalized lipodystrophy. *Leuk Lymphoma.* 2016 Jan;57(1):45-50.
30. Chan JL, Koda J, Heilig JS, **Cochran EK**, Gorden P, Oral EA, **Brown RJ**. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. *Clinical Endocrinology.* 2016 Jul;85(1):137-49.
31. Abel BS, Muniyappa R, Stratton P, Skarulis MC, Gorden P, **Brown RJ**. Recombinant human leptin (metreleptin) administration augments nocturnal LH secretion in lipodystrophy patients. *Neuroendocrinology.* 2016;103(3-4):402-7.
32. **Brown RJ, Meehan CA**, Gorden P. Leptin does not mediate hypertension associated with human obesity. *Cell.* 2015 Jul 30; 162(3) 465-6.
33. **Meehan CA, Cochran E, Mattingly M**, Gorden P, **Brown RJ**. Mild caloric restriction decreases insulin requirements in patients with type 2 diabetes and severe insulin resistance. *Medicine.* 2015 Jul;94(30)e1160.
34. **Diker-Cohen T, Cochran E**, Gorden P, **Brown RJ**. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. *J Clin Endocrinol Metab.* 2015 May;100(5):1802-10.
35. **Christensen JD, Lungu AO, Cochran E**, Collins MT, Gafni RI, Rother KI, Gorden P, **Brown RJ**. Bone Mineral Content in Patients With Congenital Generalized Lipodystrophy Is Unaffected by Metreleptin Replacement Therapy. *J Clin Endocrinol Metab.* 2014 Aug;99(8):E1493-500.

36. **Joseph J**, Shamburek RD, **Cochran EK**, Gorden P, **Brown RJ**. Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and Triglycerides. *J Clin Endocrinol Metab*. 2014 Sep;99(9):E1676-80.
37. Payne F, Lim K, Girousse A, **Brown RJ**, Kory N, Robbins A, Xue Y, Sleigh A, **Cochran E**, Adams C, Dev Borman A, Russel-Jones D, Gorden P, Semple RK, Saudek V, O'Rahilly S, Walther TC, Barroso I and Savage DB. Mutations Disrupting the Kennedy Phosphatidylcholine Pathway in Humans with Congenital Lipodystrophy and Fatty Liver Disease. *Proc Natl Acad Sci USA*. 2014 Jun 17;111(24):8901-6.
38. **Brown RJ**, Yanovski JA. Estimation of insulin sensitivity in children: methods, measures and controversies. *Pediatr Diabetes*. 2014 May;15(3):151-61.
39. Muniyappa R, **Brown RJ**, Mari A, **Joseph J**, Warren MA, **Cochran EK**, Skarulis MC, Gorden P. Effects of leptin replacement therapy on pancreatic b-cell function in patients with lipodystrophy. *Diabetes Care*. 2014 Apr;37(4):1101-7.
40. Sarkar G, Alattar M, **Brown RJ**, Quon MJ, Harlan DM, Rother KI. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes mellitus. *Diabetes Care*. 2014 Mar;37(3):666-70.
41. Nguyen TT, Jayadeva V, Cizza G, **Brown RJ**, Nandagopal R, Rodriguez LM, , Rother KI. Challenging recruitment of youth with type 2 diabetes into clinical trials. *J Adolesc Health*. 2014 Mar;54(3):247-54.
42. **Brown RJ**, **Cochran E**, Gorden P. Metreleptin improves blood glucose in patients with insulin receptor mutations. *J Clin Endocrinol Metab*, 2013 Nov;98(11):E1749-56.
43. **Safar Zadeh E**, Lungu AO, Cochran EK, **Brown RJ**, Ghany MG, Heller T, Kleiner DE, Gorden P The liver diseases of lipodystrophy: the long-term effect of leptin treatment. *J Hepatol*, 2013. 59:131-137.
44. Handelsman Y, Oral EA, Bloomgarden ZT, **Brown RJ**, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C The clinical approach to the detection of lipodystrophy - an AACE consensus statement. *Endocr Pract*, 2013.19:107-116.
45. Gorden P, **Safar Zadeh E**, **Cochran E**, **Brown RJ**. Syndromic Insulin Resistance: Models for the Therapeutic Basis of the Metabolic Syndrome and Other Targets of Insulin Resistance. *Endocrine Practice*. 2012. 18(5): p. 763-71.
46. **Kamran F**, Rother KI, Cochran E, **Safar Zadeh E**, Gorden P, **Brown RJ**. Consequences of Stopping and Restarting Leptin in an Adolescent with Lipodystrophy. *Hormone Research in Paediatrics*. 2012 Sep 1; 78(5-6): p. 320-5.
47. **Brown RJ**, Rother KI. Non-Nutritive Sweeteners and their Role in the Gastrointestinal Tract. *J Clin Endocrinol Metab*. 2012 Aug;97(8):2597-605.
48. **Brown RJ**, Walter M, Rother KI. Effects of diet soda on gut hormones in youths with diabetes. *Diabetes Care* 2012; 35:959-964.
49. Sylvetsky AC, Welsh JA, **Brown RJ**, Vos MB. Low-calorie sweetener consumption is increasing in the United States. *American Journal of Clinical Nutrition*. 2012;96(3):640-6. Epub Aug 1.
50. Foreyt J, Kleinman R, **Brown RJ**, Lindstrom R. The use of low-calorie sweeteners by children: implications for weight management. *J Nutr*. 2012 Jun;142(6):1155S-62S.
51. Cizza G, **Brown RJ**, Rother KI. Rising Incidence and Challenges of Childhood Diabetes a Mini Review. *J Endocrinol Invest*. 2012 May;35(5):541-6.
52. **Brown RJ**, Wijewickrama RC, Harlan DM, Rother KI. Uncoupling Intensive Insulin Therapy from Weight Gain and Hypoglycemia in Type 1 Diabetes. *Diabetes Technol Ther*. 2011 Apr;13(4):457-60.
53. Nandagopal R, **Brown RJ**, Rother KI. Resolution of type 2 diabetes following bariatric surgery: implications for adults and adolescents. *Diabetes Technol Ther*. 2010 Aug;12(8):671-7.
54. Gemmill JA, **Brown RJ**, Nandagopal R, Rodriguez LM, Rother KI. Clinical trials in youth with type 2 diabetes. *Pediatr Diabetes*. 2011 Feb;12(1):50-7.
55. **Brown, RJ**, M.H. Kelly, and M.T. Collins, Cushing syndrome in the McCune-Albright syndrome. *J Clin Endocrinol Metab*, 2010. 95(4): p. 1508-15.
56. **Brown RJ**, de Banate MA, Rother KI. Artificial Sweeteners: A systematic review of metabolic effects in youth. *Int J Pediatr Obes* 2010 Aug; 5(4):305-12.

57. **Brown RJ**, Walter M, Rother KI. Ingestion of diet soda before a glucose load augments glucagon-like peptide-1 secretion. *Diabetes Care* 2009;32(12):2184-6.
58. Rother KI, **Brown RJ**, Morales MM, Wright E, Duan Z, Campbell C, Hardin DS, Popovic J, McEvoy RC, Harlan DM, Orlander PR, Brod SA. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. *Diabetes Care* 2009;32(7):1250-5.
59. **Brown RJ**, Rother KI, Artman H, Mercurio MG, Wang R, Looney RJ, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. *Arch Dermatol* 2009;145(1):63-6.
60. **Brown RJ**, Sinaii N, Rother KI. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. *Diabetes Care* 2008;31(7):1403-4.
61. **Brown RJ**, Rother KI. Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. *Pediatr Diabetes* 2008;9(3 Pt 2):14-22.
62. Xu X, Zeng W, Diaz J, Lau KS, Gukovskaya AC, **Brown RJ**, et al. nNOS and Ca²⁺ influx in rat pancreatic acinar and submandibular salivary gland cells. *Cell Calcium* 1997;22(3):217-28.
63. Kevin D. Ausman, Angelo F. Benedetto, David A. Samuels, **Rebecca J. Brown**, R. Bruce Weisman. "Comparative Studies of Derivatized Fullerene Triplet States." *Recent Advances in the Chemistry and Physics of Fullerenes and Related Materials*, 1997.

Invited Reviews/Editorials

1. **Lightbourne M, Brown RJ** 2017 Genetics of Lipodystrophy. *Endocrin Metab Clin*. 2017 Jun;46(2):46:539-554.
2. Rother KI, **Brown RJ** Novel Forms of Lipodystrophy: Why should we care? *Diabetes Care*, 2013. 36:2142-2145.
3. Sylvetsky A, Rother KI, **Brown R**. Artificial sweetener use among children: epidemiology, recommendations, metabolic outcomes, and future directions. *Pediatr Clin North Am*. 2011 Dec;58(6):1467-80.
4. Rother KI, **Brown RJ**. Selecting weight loss surgery based on HDL genotype--are we there yet? At the brink of "personalized surgery". *J Clin Endocrinol Metab*. 2011 Jun;96(6):1664-7.
5. **Brown RJ**, Rother KI. Clinical Trial Report: The Many Faces of Diabetes in American Youth: Type 1 and Type 2 Diabetes in Five Race and Ethnic Populations: the SEARCH for Diabetes in Youth Study. *Current Cardiovascular Risk Reports* 2010;4:175-177.

Book Chapters

1. Hodes A, **Brown R**, Cochran C, Zilbermint M. Lipodystrophy Due to PPAR- γ Gene Mutation. In: Draznin B. *Atypical Diabetes: Pathophysiology, Clinical Presentations, and Treatment Options*; American Diabetes Association;; 2018.
2. **Brown RJ**, Gorden P 2015 Leptin Therapy in Patients with Lipodystrophy and Syndromic Insulin Resistance. In: Dagogo-Jack MDS ed. *Leptin: Springer International Publishing*; 225-236
3. Sylvetsky AC, **Brown RJ**, Rother KI 2014 Biological and Health Effects of Nonnutritive Sweeteners. In: *Dietary Sugars and Health: CRC Press*; 99-114

Active Clinical Protocols

1. Associate Investigator, Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLR4-MAS, Still's-like Diseases, and other Undifferentiated Autoinflammatory Diseases) (2017-present)
2. Principal Investigator, A Randomized, Double Blind, Placebo-Controlled Study to Assess Efficacy, Safety and Tolerability of ISIS 304801 in Patients with Partial Lipodystrophy with an Open-Label Extension (2016-present)
3. Principal Investigator, Thyroid hormone to induce non-insulin mediated glucose disposal in patients with insulin receptor mutations (2015-present)
4. Principal Investigator, Compassionate use of metreleptin in previously-treated patients with generalized lipodystrophy (2015-present)

5. Principal Investigator, Compassionate use of metreleptin in previously-treated patients with partial lipodystrophy (2015-present)
6. Principal Investigator, Short-term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake (2013-present).
7. Principal Investigator, Effect of Leptin Therapy in the Treatment of Severe Insulin Resistance (2012-present).
8. Principal Investigator, Studies of Molecular Genetics of Insulin Secretion, Insulin Action, and Diabetes Mellitus (2012-present).
9. Associate Investigator, Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy (2012-2014).
10. Lead Associate Investigator, Metabolic Effects of Non-nutritive Sweeteners (2010-present).
11. Associate Investigator, Effects of Caloric Restriction Alone versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients with Diabetes Mellitus, (2010-present).
12. Associate Investigator, Natural History of Type 2 Diabetes Mellitus in Children and Young Adults (2007-present).